FN1 drives NSCLC metastasis through integrin-mediated FAK/SRC signaling while conferring cisplatin resistance via Wnt/β-catenin activation through direct integrin-β1 binding, in addition, silencing of FN1 sensitizes resistant cells by reducing IC50 values and restoring apoptosis [37]. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.